257 related articles for article (PubMed ID: 25913134)
1. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
[TBL] [Abstract][Full Text] [Related]
2. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
4. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of serum squamous cell carcinoma antigen in the diagnosis, treatment and prognosis of cervical squamous cell carcinoma].
Luan XM; Zhang Y; Wang SZ; Wang N; Li W; Zhang Q; Wei H; Zhang SL
Zhonghua Yi Xue Za Zhi; 2012 May; 92(19):1330-3. PubMed ID: 22883121
[TBL] [Abstract][Full Text] [Related]
10. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
11. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of serum squamous cell carcinoma antigen in patients with early cervical squamous cell carcinoma].
Li D; Xu XX; Yan DD; Yuan SH; Lou HM
Zhonghua Zhong Liu Za Zhi; 2019 May; 41(5):357-362. PubMed ID: 31137169
[No Abstract] [Full Text] [Related]
13. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of serum squamous cell carcinoma antigen with clinico-pathological features and prognosis of squamous cell carcinoma of uterine cervix].
Xiong Y; Liang LZ; Zheng M; Wei M; Shen Y
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):29-33. PubMed ID: 17331418
[TBL] [Abstract][Full Text] [Related]
15. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pre-treatment CYFRA 21 - 1 and SCC-Antigen assay in primary cervical carcinoma - a preliminary report.
Puthucode-Easwaran S; Naik R; Athavale R; Handley G; Lopes A; Godfrey K; Hatem M
J Obstet Gynaecol; 2005 Jul; 25(5):486-8. PubMed ID: 16183586
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung.
Park SY; Lee JG; Kim J; Park Y; Lee SK; Bae MK; Lee CY; Kim DJ; Chung KY
Lung Cancer; 2013 Feb; 79(2):156-60. PubMed ID: 23206831
[TBL] [Abstract][Full Text] [Related]
18. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer.
Reesink-Peters N; van der Velden J; Ten Hoor KA; Boezen HM; de Vries EG; Schilthuis MS; Mourits MJ; Nijman HW; Aalders JG; Hollema H; Pras E; Duk JM; van der Zee AG
J Clin Oncol; 2005 Mar; 23(7):1455-62. PubMed ID: 15735121
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers.
Shimada Y; Watanabe G; Kawamura J; Soma T; Okabe M; Ito T; Inoue H; Kondo M; Mori Y; Tanaka E; Imamura M
Oncology; 2005; 68(2-3):285-92. PubMed ID: 16015046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
